A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)
复制标题
DOI：
10.1185/030079907x242809
复制
发表时间：
2007-12-01
影响因子：
2.3
通讯作者：
Sriratanasathavorn, Charn
中科院分区：
文献类型：
--
作者：
Zhu, Jun-ren;Tomlinson, Brian;Sriratanasathavorn, Charn
背景资料。大多数研究他汀类药物益处的研究都集中在北美和欧洲人群。这项研究的重点是评估瑞舒伐他汀和阿托伐他汀在亚洲患者中的降脂效果。目的：低密度脂蛋白-C值的他汀类药物直接比较：对罗舒伐他汀治疗的评估(DISCOVER)-亚洲研究是评估起始剂量他汀类药物在全球不同国家达到目标血脂水平的有效性的九项独立研究之一。Discovery-Asia是一项在中国、香港、韩国、马来西亚、台湾和泰国进行的为期12周的随机开放平行分组研究。结果：共有1482名患有原发性高胆固醇血症和高心血管风险(20%/10年、2型糖尿病或冠心病病史)的成年人按2：1比例随机接受瑞舒伐他汀10 mg每日1次治疗。或阿托伐他汀10 mg od。达到1998年欧洲联合工作组低密度脂蛋白胆固醇目标的患者百分比
Background. Most studies investigating the benefits of statins have focused on North American and European populations. This study focuses on evaluating the lipid-lowering effects of rosuvastatin and atorvastatin in Asian patients.Objectives: The Direct Statin COmparison of LDL-C Values: an Evaluation of Rosuvastatin therapY (DISCOVERY)-Asia study is one of nine independently powered studies assessing the efficacy of starting doses of statins in achieving target lipid levels in different countries worldwide. DISCOVERY-Asia was a 12-week, randomised, open-label, parallel-group study conducted in China, Hong Kong, Korea, Malaysia, Taiwan, and Thailand.Results: A total of 1482 adults with primary hypercholesterolaemia and high cardiovascular risk (> 20%/ 10 years, type 2 diabetes, or a history of coronary heart disease) were randomised in a 2:1 ratio to receive rosuvastatin 10 mg once daily (o.d.) or atorvastatin 10 mg o.d. The percentage of patients achieving the 1998 European Joint Task Force low-density lipoprotein cholesterol (LDL-C) goal of